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ABSTRACT
Objective: To assess the efficacy and safety of Insuflow®
(Georgia BioMedical, Inc.) filter heater hydrator device in
reducing the incidence, severity and extent of hypother-
mia, length of recovery room stay and postoperative pain
at the time of laparoscopy.
Design: Prospective, randomized, blinded, controlled
multi-center study. Patients underwent gynecologic pro-
cedures via laparoscopy; surgeons, anesthesiologists and
recovery room personnel assessed the results.
Setting: Seven North American institutions.
Patients: Seventy-two women for safety evaluation and
efficacy studies.
Interventions: Intraoperative pre-conditioning of laparo-
scopic gas with the Insuflow® device (treatment) or stan-
dard raw gas (control) during laparoscopic surgery and
postoperatively.
Main Outcome Measures: Incidence, severity and extent
of hypothermia, postoperative pain perception and length
of recovery room stay.
Results: The Insuflow® group had significantly less intra-
operative hypothermia, reduced length of recovery room
stay and reduced postoperative pain. Pre-conditioning of
laparoscopic gas by filtering heating and hydrating was
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well tolerated with no adverse effects. The safety profile
of the Insuflow® pre-conditioned gas showed significant
benefits compared to currently used raw gas.
Conclusions: Pre-conditioning laparoscopic gas by fil-
tering heating and hydrating with the Insuflow® device
was significantly more effective than the currently used
standard raw gas and was safe in reducing or eliminating
laparoscopic-induced hypothermia, shortening recovery
room length of stay and reducing postoperative pain.
Key Words: Gas hydration, Laparoscopic hypothermia,
Pain, Length of stay, Laparoscopy, Peritoneum.
INTRODUCTION
Changes induced by the currently used raw gas during
insufflation to create a pneumoperitoneum induces
laparoscopic hypothermia, causes postoperative pain
and results in prolonged recovery room stay.
1-
7 Because
the gas must be bone dry, there is a stark difference
between the characteristics of this regulated raw gas and
the normal physiologic condition of the abdomen that
causes this dramatic contrast. The difference between
the temperature of standard raw gas of 21 degrees
Centigrade (C) and 37.0 degrees C core temperature and
no water vapor versus intra-abdominal steady state satu-
ration results in alterations that upset normal abdominal
homeostasis. These changes are iatrogenically induced
due to these differences and the insufflation gas delivery
system. The result is alterations that influence develop-
ment of hypothermia, effect recovery room length of stay
and postoperative pain perception. The annual cost of
correcting for the iatrogenic intra- and postoperative con-
sequences of laparoscopy due to prolonged recovery
room stay and productive work loss in the United States
is estimated to be between $2.26-1.56 billion per year.
Changes that improve laparoscopic gas characteristics
from its raw state to a more physiologic condition influ-
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ences surgical outcome, reduces pain, has cost benefit
and improves the level of safety. This recognition is
compelling and establishes a new standard of care.
Principles of any surgery including laparoscopy include
gentle tissue handling, reduction of foreign body con-
tamination and prevention of tissue drying. The use of
standard unconditioned gas is a contradiction to these
long-standing principles. In the current raw state the gas
and its delivery system contribute to foreign body con-
tamination and tissue dessication. Maintaining or repro-
ducing the normal physiologic intra-abdominal environ-
ment (contaminant free, warm and moist) is a standard
that can be achieved and should be met.
Laparoscopic gas filters were introduced in 1989.
1 It is
long understood that the laparoscopic gas is a contribu-
tor to surgical hypothermia.
5 Attempts to correct laparo-
scopic hypothermia have been found inadequate by only
heating the gas. It is known that without hydration only
heating the gas has little effect on preventing laparo-
scopic hypothermia.
2,
3 It is necessary to use heated gas
containing water vapor to have maximal intraoperative
heat preservation and be appropriate for tissue surfaces
to result in minimizing tissue damage. The detrimental
changes that occur due to the raw gas require modifica-
tion by heating and hydrating.
2,
3 A method to deliver
pre-conditioned gas that accomplishes these necessary
changes that modify standard raw gas to one more
appropriate for laparoscopic procedures is advocated.
2,
3
The use of heated gas compared to the current raw gas
is found to decrease postoperative pain.
6-
8 Methods that
only heat laparoscopic gas in the insufflator or in
warmed gas tubing are only marginal in their ability to
heat, transmit and maintain the gas at a physiologic tem-
perature when it enters the abdomen.
6 To the best of
our knowledge, only one report describes the use of
heated humidified gas which was shown to reduce the
time to return to normal function and decrease postop-
erative pain.
7 A recently approved method and device is
available that filters, heats and hydrates laparoscopic gas
to a more physiologic condition as it enters the peri-
toneal cavity. The purpose of this study is to assess the
efficacy of this device (Insuflow®), a method that pre-
conditions by filtering heating and hydrating endoscopic
gas, and to determine its effect in reducing laparoscopic-
induced hypothermia, reducing pain and shortening
recovery room length of stay.
MATERIALS AND METHODS
Study Design
This prospective, randomized, blinded, controlled, multi-
center study compared the efficacy and safety of the
Insuflow device regarding the incidence, extent and
severity of laparoscopic-induced hypothermia, postoper-
ative pain perception and effect on the length of recov-
ery room stay.
Randomization
Before the procedure, patients at each center were ran-
domly assigned to the Insuflow® (treatment group) or
the raw gas (control group).
The Insuflow system has three components: an AC/DC
converter, a controller circuit and a disposable filter
heater hydrator (Insuflow®) device. The converter deliv-
ers reliable safe electric current and is connected to a
controller circuit box that adapts and retrofits to any
insufflator. The Insuflow device attaches to the con-
troller circuit box and insufflator. It provides filtration by
a hydrophobic 0.2 micron CO2 Guard® filter and is nine
feet long. The heating and hydrating occurs within five
centimeters of the intra-abdominal gas delivery point for
delivery of optimally conditioned gas. The small heater
hydrator section is filled with eight cubic centimeters of
warm sterile water, normal saline or lactated ringers solu-
tion for each 150 liters of gas insufflation used during the
procedure. The insufflator settings are independent of
and not effected by the Insuflow® device. The gas is
delivered to the patient at 36.2° C (97.2° F) and 95% rel-
ative humidity at constant low flow demand for 150 liters
of gas (2 hours 30 minutes average). The intra-abdomi-
nal delivered gas characteristics can vary due to the
demands placed on the device by the user and are
dependent on gas flow rate, frequency and amount of
gas evacuated.
Test Conditions
All centers used their own insufflators. All surgeons
determined their own parameter settings for gas insuffla-
tion (flow rates and intra-abdominal pressure), followed
their own institutional and personal standards for surgi-
cal procedures, set their own operating room tempera-
tures, irrigation use and gas evacuation criteria. All anes-
thesiologists followed and determined anesthetic charac-
teristics and individual methodologies for the surgical
procedure. Individual institutional recovery room proto-
322 JSLS (1998)2:321-329JSLS
cols were followed. No surface warming devices were
used in any of the Insuflow® patients. Operating room
ambient temperature and humidity were recorded and
not modified during the procedures.
Study Population
Eight principal investigators at seven institutions enrolled
72 adult women in the Insuflow® and control groups
from January 15, 1998 to May 29, 1998. The patients
were adult women between 18 and 48 years of age.
Patients' weights were between 97 and 252 pounds. All
patients had laparoscopy. The protocol excluded preg-
nant or cancer patients.
Surgery
The methodology and care of all patients was consistent
with the investigators' standard surgical and medical
practices. The methodology and care of patients in the
two groups differed only in the use of the Insuflow®
device for the study group. Data was kept of various
characteristics of the procedure, insufflation and medica-
tion use.
Evaluation
Preoperative evaluation included medical and surgical
history, vital signs (temperature, blood pressure and
heart rate), laboratory values (complete blood count and
pregnancy test), eligibility criteria and informed consent
documentation.
Intraoperative evaluation was done following each insti-
tution and physician's established practices. Evaluation
of the following parameters was done every ten minutes
during and after surgery including operating room tem-
perature and humidity, patient core temperature moni-
toring by endotracheal temperature probe, insufflation
gas volume, flow rate and pressure and irrigation volume
consumed. Pain questionnaires were used with a visual
analogue scale having scores from 0 (no pain) to 10
(unbearable pain) using established protocols.
9
Post-anesthesia recovery room evaluation followed each
institution's established protocols and included tempera-
ture, pain medication use, time in recovery room and
pain perception.
Evaluation of Safety
Throughout the study no adverse events occurred in the
Insuflow® group. Physician and patient evaluations were
solicited and evaluated.
Statistical Analysis
All variables were summarized with descriptive statistics,
including number, mean, median, standard deviation,
range of continuous variables and number and percent-
age in each category.
RESULTS
There were no statistically significant differences
between the groups in demographic information.
Surgical evaluations included diagnoses of uterine
leiomyomata, infertility, pelvic adhesions and
endometriosis. A total of 72 patients were in the study
at seven different centers.
Figure la. No Insuflow®.
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Figure 1b. Insuflow® device used.
All patients started their procedures in a euthermic state.
Operating room temperature ranged from 19.5-21.5° C
(67.1-70.7° F). Relative humidity ranged from 42-59%.
Operating time ranged from 38 to 262 minutes. The total
intraoperative temperature drop in the Insuflow group
ranged from 0.0-0.6° C (average total procedure loss 0.3°
C, less than 0.1° C per hour) and 0.3-2.06° C (average
total loss per procedure was 1.64° C, more than 0.6° C
per hour) for the raw gas group. Carbon dioxide gas vol-
ume ranged from 82-680 liters. Irrigation volume ranged
from 0.3-12 liters and at time of use was 26° C (78.8° F)
or less. All cases utilized laser or electro-surgical devices.
Figures 1-3 depict findings for three procedures in both
groups. While procedures less than 35 minutes had lit-
tle or no hypothermia, pain profiles for these short pro-
cedures were still statistically significantly improved in
the Insuflow® group.
A total of 88.9% of questionnaires were completed. A
significant difference in postoperative pain was found in
the raw gas versus the Insuflow® warmed hydrated gas
group. Consistently lower pain values were found in the
Insuflow® group at all time intervals up to three days.
Pain intensity was directly related to gas volume used
and length of surgery in both groups but was statistical-
ly significant and reduced in the Insuflow® group.
Shoulder and sub-phrenic pain were significantly
reduced in the Insuflow® group at all time parameters
compared to the standard raw gas group regardless of
volume of gas consumed or length of surgery (Figure 4).
Efficacy
The Insuflow® group had a statistically significant reduc-
tion in intraoperative and postoperative hypothermia for
procedures lasting over one hour, reduced pain percep-
tion postoperatively for all procedures regardless of
length of surgery or gas consumed and shorter recovery
room stay compared to the standard raw gas group.
There was no reduction or enhancement effect of laser
or electrosurgery with the Insuflow device.
Safety
The safety profile of the Insuflow® device showed an
improvement over the currently used raw gas group. No
adverse effects were noted intraoperatively or postoper-
atively in the Insuflow group. Statistically significant dif-
ferences were noted between the groups regarding
hypothermia, pain perception and recovery room length
of stay. These parameters showed that the Insuflow®
group had significantly less intraoperative and postoper-
ative hypothermia (8.3% versus 94.4%), postoperative
pain improvement (56%) and shorter recovery room
length of stay (88.9% versus 33.3% less than one hour).
No Insuflow® patient had a recovery room stay longer
than two hours. No Insuflow® patients became more
than mildly hypothermic (36.0° C or 96.8° F). In the raw
gas group, 44.4% were in the recovery room for two
hours, 16.7% for three hours and 5.6% over four hours
(Figure 5). For the raw gas group, 100% of patients
were mildly hypothermic if the procedure was longer
than 1 hour and 30 minutes, or if more than 110 liters of
gas were used.
DISCUSSION
Caeteris parabus, insufflation with standard current raw
gas into the peritoneal cavity, results in physiologic
changes directly attributable to the nature of the gas, ie,
tissue dessication, hypothermia and postoperative pain.
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Operating room temperature 20.1° C.
12 liters 23.9° C irrigation.
No rewarming devices.
0.38° C total temperature loss.
3 hours 40 minutes operating time.
1 hours 30 minutes recovery room stay.
Insuflow® used.
Operating room temperature 20.3° C.
9 liters of 24.4° C irrigation.
No rewarming device.
0.75° C total temperature loss.
3 hours 15 minutes operating time.
2 hours 45 minutes recovery room time.
Raw gas used.
Figure 2. Insuflow® versus raw gas comparison.
Insuflow®
66.4 liter of CO2 used.
1000 cc irrigation.
60 minutes operating time.
No rewarming device.
No Insuflow®
95.5 liters of CO2 used.
300 cc irrigation.
45 minutes operating time.
No rewarming device.
Figure 3. Body Temperature.
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Figure 4. Shoulder pain.
The gas standard as promulgated by the United States
Pharmacopeia and National Formulary defines gas char-
acteristics for purity and requires less than 200 parts per
million of water vapor (bone dry).
1
0 Surgical principles
and techniques that influence laparoscopic outcome
include attention to detail, gentle minimal tissue han-
dling, meticulous hemostasis, reduction of foreign body
contamination, prevention of tissue drying or dessication
and magnification when appropriate.
11,1
2 Therefore, it is
important and beneficial to maintain or reproduce the
normal physiologic environment of the abdomen during
any surgery to ensure optimal outcome, including
laparoscopy. This is not the case using the current raw
gas. The gas delivery systems further compound the
problem by throttling gas to extremely high flow rates.
The normal abdominal environment is particle free, 37° C
and has tissue surfaces moist with peritoneal fluid. The
current standard raw gas (usually carbon dioxide) and
delivery systems used to create a laparoscopic pneu-
moperitoneum contain contaminants (inorganic and
organic debris from cylinders and insufflators), is 21° C
(69.8° F) and is bone dry (0.0002% water vapor).
1,13,1
4
The steady state of high water vapor content in the
abdomen with the peritoneal fluid covering tissue sur-
faces is severely altered by insufflation of the standard
raw bone dry gas. Insufflation with CO2 in rigorous
experimental studies demonstrated significant fall in core
temperature.
2 Experiments further demonstrate these
differences by measuring and comparing the temperature
and relative humidity differences for gas insufflation
using cold dry gas versus warmed humidified gas to be
0.6° C per hour.
3 Prevention of water loss is the most
important factor in preventing laparoscopic hypothermia.
The difference between the warm moist tissue surfaces
and the cool dry gas causes rapid evaporation resulting
in tissue dessication, mesothelial damage and loss of
peritoneal cells with exposure of the underlying connec-
tive tissue matrix. Immediately after peritoneal drying
there is loss of mesothelial cells on the cecum.
1
5
The laparoscopic gas delivery system throttles gas
through small apertures at high flow rates resulting in a
nozzle effect and jet streaming of the gas. The fluid
dynamics of the gas delivered through constricted aper-
tures at high flow rates on wet tissue surface leads to
rapid evaporation, heat loss resulting in hypothermia, tis-
sue dessication and peritoneal damage. This is the case
when gas is delivered through a Veress needle, small
diameter trocars or through ports that have a similar-
sized object entering through a port (10 mm laparoscope
through a 10 mm trocar). The result is extremely high
flow jet streams of cold dry gas over wet tissue surfaces,
severe local tissue hypothermia and generalized evapo-
rative hypothermic effects.
1
6 This creates a condition
akin to a wind chill effect from the nozzling of gas
through small diameter openings onto the peritoneal sur-
faces. Larger, unobstructed gas entry ports with low gas
flow rates reduce deleterious effects on tissue from gas
insufflation.
Factors that surgeons have control over that contribute to
these problems are gas flow rate demanded, insufflator
settings, amount of gas consumed, length of surgical
exposure, gentleness of tissue handling, operating room
temperature and temperature of irrigation solutions.
Factors that contribute to operative hypothermia over
which there is no control is patient age, size, pre-existing
metabolic conditions and prior medication use.
Awareness by anesthesiologists of operative hypothermia
has long been noted. Anesthesiologists recognized the
need for pre-conditioning gas delivered to the respirato-
ry tract in the 1950's. It was determined that adding
water vapor to gases prevented damage to the trachea
and lung tissue. Heating and humidification devices that
prevent tissue drying and hypothermia effects from res-
piratory tract gas delivery have been standards of care for
326 JSLS (1998)2:321-329JSLS
Figure 5. Comparison of length of stay standard raw gas versus heated hydra ted pre-conditioned gas.
over 35 years. The most recent effort to help control
intraoperative laparoscopic hypothermia is the addition
of surface convection warming devices. While any and
all attempts to reduce hypothermia are desirable, this is
an attempt to cure a problem after it has occurred. The
prevention of a deleterious iatrogenic effect before it
occurs is a more prudent approach. Pre-conditioning gas
with heat and water vapor has been advocated
2,
3 and is
a practical technologic cost-effective reality with the
Insuflow® device. The device is efficient, rapidly
responds to use demands of insufflation and maintains a
more normal intra-abdominal condition compared to
using raw gas.
Intraoperative hypothermia requires extensive monitor-
ing, care and time in the post-anesthesia recovery room.
Postoperative hypothermia has both metabolic and eco-
nomic costs. Normal core body temperature is 37° C.
Clinical hypothermia is defined as a core temperature
less than 36° C (96.8° F).
1
7 Changes resulting from mild
and moderate hypothermia (32-35° C) are significant.
Surgery stresses normal body temperature, normal regu-
latory mechanisms are modified and the balance of heat
production and heat loss is altered. The result is a shift
of temperature outside the normal physiologic range.
The thermoregulatory system attempts to maintain the
core temperature in a 0.2° C range. Intraoperative main-
tenance of the preoperative normothermic state is neces-
sary to counteract the negative effects of hypothermia as
they occur during surgery. Even mild operative
hypothermia influences skin infection rate and perioper-
ative wound infection by directly impairing immune
function and vasoconstriction (by decreasing partial pres-
sure of oxygen in tissues), induces hypokalemia, impairs
myocardial function, depresses respiration, influences
nitrogen balance,
1
8 depletes clotting factors, induces
thrombocytopenia,
1
9 decreases activation of the coagula-
tion cascade,
1
9 decreases collagen synthesis,
2
0 impairs
chemotaxis and phagocytosis of neutrophils and
decreases the production of antibodies. Mild hypother-
mia alters drug metabolism and pharmacokinetics, sig-
nificantly prolongs recovery room time
21,2
2 and is associ-
ated with postoperative shivering, substantial adrenergic
activation
2
3 and patient discomfort.
2
4 A core temperature
decrease of 1.5° C causes a three times increase in ven-
tricular tachycardia,
2
5 increased postoperative ventilation,
oxygen consumption and changes peripheral vascular
tone.
The normal thermal steady state is one in which heat loss
is equal to metabolic heat production. This is not uni-
formly distributed during surgery. Thermoregulatory
mechanisms try to keep the core temperature nearly con-
stant while the periphery is simultaneously at a lower
temperature because of tonic vasoconstriction.
2
6 Due to
the evaporative cooling effects caused by the dry laparo-
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scopic gas, intra-abdominal conditions are altered, thus
decreasing the heat available for redistribution. This
upsets the normal balance of heat retention and loss.
The heat normally sequestered in the abdomen is lost by
vaporization of water from peritoneal surfaces, gas
removal and as yet undetermined reflexes that contribute
to thermal instability. This normal core heat sink is then
unavailable for postoperative thermoregulation and
redistribution and leads to a cool periphery and a cool
core compounding the hypothermic effect. The use of
heated laparoscopic gas containing water vapor allows
for maintenance of the normal heat sink and reduction
or prevention of the induced hypothermia.
The alterations caused by peritoneal dessication result in
intact mesothelial cells becoming absent from bowel sur-
faces immediately after drying.
1
5 The effect of damaged
peritoneum is denuded areas with release of chemically
active kinins and prostaglandins that contribute to post-
operative pain. The damaged peritoneum increases the
susceptibility to adhesion formation from apposing
defects and probably contributes to de-novo adhesion
formation. The application of heated gas containing
water vapor during insufflation allows for maintenance
of the normal intra-abdominal condition to maximize
peritoneal preservation at laparoscopy.
Postoperative pain intensity has been shown to decrease
when heated laparoscopic gas is utilized.
6 Heated
humidified gas has been shown to improve return to nor-
mal activities by 54% in cholecystecomy procedures and
significantly reduce pain extending to the third postop-
erative day.
7 The conclusions of these studies are that
warmed CO2 gas leads to significant reduction of pain,
and humidified insufflation gas reduces postoperative
pain and reduces postoperative recovery time.
6,
7 This
study reaches the same conclusions by using a device
that combines the benefits of both heating and hydrating
the gas. Exactly how the use of heated and hydrated gas
reduces pain is not clear. It is postulated that the loss of
peritoneal integrity due to dessication results in release
of chemical agents responsible for pain perception.
Temperature-sensitive transmitters may additionally
account for the loss of integrity of temperature regulation
and pain sensation. Further studies are necessary to elu-
cidate the etiology of these effects and the benefits
afforded by gas pre-conditioning.
Since the advisability of a procedure or intervention is a
scientific judgement, clinical effectiveness is necessary.
The effectiveness of heated hydrated gas is demonstrat-
ed in this and other studies. It is also important to eval-
uate economic utility as a factor in making medical
judgements. Analysis of outcomes from previous studies
show that the use of the conditioned gas at laparoscopy
favorably influences outcomes (reducing pain and rapid
recovery and return to work).
6,
7 Use of the Insuflow®
device was less expensive in this study and resulted in
better outcomes than using the current standard raw gas.
Economic consequences (costs) of hypothermia have
been previously reported.
2
7 These include increased
time in the recovery area, use of alternative warming
methods and increased need for analgesic medicines.
6
The financial penalty for not using pre-conditioned gas
includes time, equipment, use of modifying techniques
that only partially treat the effect and not the cause and
slower return to full function. The economic savings per
procedure using the Insuflow® device on every
laparoscopy far exceeds the costs of the current methods
it replaces, making it clearly a better strategy. There is
decreased need to de-fog the laparoscope lens because
the intra-abdominal dew point is not reached, eliminat-
ing the need for de-fogging agents. Time, operating
room costs and frustration are saved with not having to
de-fog. Hypothermia is reduced or eliminated, making
surface warming methods less necessary. Recovery
room time is decreased as a result of the patients' more
euthermic postoperative state. The need for postopera-
tive analgesic medicines is reduced because of signifi-
cantly reduced pain perception. Return to full function
activities is improved by over 50%.
In summary, laparoscopic procedures that induce
hypothermia are favorably influenced by heated hydrat-
ed gas and also reduce pain and shorten recovery room
stay significantly. Laparoscopic procedures that minimal-
ly affect hypothermia reduce postoperative pain and
shorten recovery room stay when heated hydrated gas is
used. The Insuflow® device pre-conditions laparoscopic
gas by heating and hydration, significantly reduces with
regard to incidence, severity and extent of postoperative
pain, shortens recovery room length of stay and reduces
hypothermia by maintaining a more normal physiologic
intra-abdominal state. The safety profile of heated
hydrated gas exceeds that of current standard raw gas.
The use of heated hydrated gas during laparoscopy is a
significant breakthrough that is beneficial to the patient's
outcome.
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